Dolutegravir - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2014-11-03 11:26:18 Medicine Intel Viiv Integrase ViiV Healthcare Shionogi New Drug Application HIV Food and Drug Administration Dolutegravir Integrase inhibitors Pharmaceutical sciences Biology		Add to Reading List Source URL: shionogi616.tew-staging.com Download Document from Source Website File Size: 26,08 KB Share Document on Facebook

	June 17, 2009 Chemicals Targeting an HIV‐1 Nef/Host Cell Kinase Complex as Novel Anti‐ Retroviral Compounds Damilola A. Adepegba, Department of Natural Sciences, University of Maryland DocID: 1qLnJ - View Document
	GENERAL CONFORMITY CERTIFICATE Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a reasonable testing program, the product referenced in this certificate complies with applicable regulations DocID: 1aVDG - View Document
	Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav DocID: 1ai1w - View Document
	Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference Positive Antiviral Responses Demonstrated in Interim 16 Week Analysis from SPRING-1 S DocID: 1a5kT - View Document
	Once‐Daily Dolutegravir is Non‐Inferior to Twice‐Daily Raltegravir in Treatment‐Naïve Adults with HIV‐1  DocID: 1a5bW - View Document